Salivary HLA-DQA1*05 Genotyping and Anti-TNF Treatment Outcomes in Inflammatory Bowel Disease: An Ambispective Cohort Study with Long-Term Follow-Up

Background/Objectives: HLA-DQA1*05 carriage has been associated with immunogenicity to anti-TNF agents in inflammatory bowel disease (IBD), but real-world data are inconsistent. We assessed whether carriage, determined by salivary genotyping, was associated with anti-TNF effectiveness, persistence and safety. Ambispective here denotes prospective ascertainment of the exposure combined with retrospective capture of outcomes. Methods: This was a single-centre ambispective cohort study of 170 adults with IBD treated with infliximab or adalimumab as their first biologic. HLA-DQA1*05 was genotyped prospectively from saliva (July 2024–April 2025); outcomes were retrieved retrospectively. Primary non-response (PNR), secondary loss of response (SLOR), treatment persistence and adverse events were compared by genotype using Kaplan–Meier and multivariable Cox analyses. Results: Of 167 patients with a conclusive genotype, 74 (44.3%) were carriers; median treatment exposure was 78.5 months. PNR occurred in 12.2% of carriers and 7.5% of non-carriers (odds ratio [OR] 1.70, 95% confidence interval [CI] 0.60–4.81), and SLOR in 53.8% and 47.7% of initial responders (OR 1.28, 95% CI 0.67–2.44). Carriage was not associated with time to SLOR (adjusted hazard ratio [HR] 1.76, 95% CI 0.97–3.21) or with all-cause discontinuation (adjusted HR 0.98, 95% CI 0.62–1.55). Conclusions: In this selected, real-world cohort with long-term follow-up, HLA-DQA1*05 carriage determined in saliva was not associated with anti-TNF failure or treatment persistence, although clinically relevant effects are not excluded. Establishing the clinical utility of HLA-DQA1*05 testing will require prospective genotyping before treatment, with systematic immunogenicity assessment.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2026-11-19
DOI
https://doi.org/10.3390/jcm15229064
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Salivary HLA-DQA1*05 Genotyping and Anti-TNF Treatment Outcomes in Inflammatory Bowel Disease: An Ambispective Cohort Study with Long-Term Follow-Up

Cristina Mira, Lucía Madero-Velázquez, Ana Gutiérrez, V Ictor Moreno-Torres' et al.
Journal of Clinical Medicine
Inflammatory Bowel Disease
article

Salivary HLA-DQA1*05 Genotyping and Anti-TNF Treatment Outcomes in Inflammatory Bowel Disease: An Ambispective Cohort Study with Long-Term Follow-Up

Cristina Mira, Lucía Madero-Velázquez, Ana Gutiérrez, V Ictor Moreno-Torres', Belén Herreros, Roser Muñoz, O. Belén‐Galipienso, Isabel García-García, Antonio García-Trueba
article en

Abstract

Background/Objectives: HLA-DQA1*05 carriage has been associated with immunogenicity to anti-TNF agents in inflammatory bowel disease (IBD), but real-world data are inconsistent. We assessed whether carriage, determined by salivary genotyping, was associated with anti-TNF effectiveness, persistence and safety. Ambispective here denotes prospective ascertainment of the exposure combined with retrospective capture of outcomes. Methods: This was a single-centre ambispective cohort study of 170 adults with IBD treated with infliximab or adalimumab as their first biologic. HLA-DQA1*05 was genotyped prospectively from saliva (July 2024–April 2025); outcomes were retrieved retrospectively. Primary non-response (PNR), secondary loss of response (SLOR), treatment persistence and adverse events were compared by genotype using Kaplan–Meier and multivariable Cox analyses. Results: Of 167 patients with a conclusive genotype, 74 (44.3%) were carriers; median treatment exposure was 78.5 months. PNR occurred in 12.2% of carriers and 7.5% of non-carriers (odds ratio [OR] 1.70, 95% confidence interval [CI] 0.60–4.81), and SLOR in 53.8% and 47.7% of initial responders (OR 1.28, 95% CI 0.67–2.44). Carriage was not associated with time to SLOR (adjusted hazard ratio [HR] 1.76, 95% CI 0.97–3.21) or with all-cause discontinuation (adjusted HR 0.98, 95% CI 0.62–1.55). Conclusions: In this selected, real-world cohort with long-term follow-up, HLA-DQA1*05 carriage determined in saliva was not associated with anti-TNF failure or treatment persistence, although clinically relevant effects are not excluded. Establishing the clinical utility of HLA-DQA1*05 testing will require prospective genotyping before treatment, with systematic immunogenicity assessment.

Journal of Clinical MedicineVol. 15(22)
Instituto de Salud Carlos III (ES), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES), Hospital General Universitario de Alicante Doctor Balmis (ES), Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL) (ES)
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon